Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo

Alternative Names: CS-8635; Sevikar HCT; Sevikar Plus; Tribenzor

Latest Information Update: 05 Nov 2023

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Daiichi Sankyo Company
Developer Daewoong Pharmaceutical; Daiichi Sankyo Company
Class Antihypertensives; Benzothiadiazines; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Jan 2022 Olmesartan medoxomil/amlodipine/hydrochlorothiazide licensed to Cosette Pharmaceuticals in USA
10 Jan 2019 Chemical structure information added
31 Dec 2018 Sungkyunkwan University School of Medicine and Daiichi Sankyo completes the phase III trial in Hypertension in South Korea (PO) (ISRCTN51756760)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com